FY2027 EPS Estimates for Gilead Sciences Lowered by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Erste Group Bank lowered their FY2027 EPS estimates for Gilead Sciences in a research report issued to clients and investors on Monday, July 27th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will earn $9.59 per share for the year, down from their previous estimate of $9.65. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.77) per share.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Truist Financial dropped their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research note on Monday, July 6th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $133.00 to $155.00 in a report on Monday, July 6th. Finally, Daiwa Securities Group dropped their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $158.30.

Gilead Sciences Trading Up 2.9%

Shares of GILD stock opened at $134.32 on Wednesday. The company has a market capitalization of $166.77 billion, a P/E ratio of 18.30 and a beta of 0.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The business’s 50 day moving average is $129.64 and its two-hundred day moving average is $135.75. Gilead Sciences has a twelve month low of $108.46 and a twelve month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the previous year, the firm posted $1.81 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,000 shares of company stock worth $8,687,140 in the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of GILD. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $26,000. Wealth Preservation Advisors LLC increased its stake in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares in the last quarter. Finally, Wilkerson Advisory Group LLC raised its position in shares of Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 78 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Morgan Stanley maintained an “overweight” rating on Gilead and reduced its price target only slightly, from $166 to $165. The target still implies substantial upside from recent trading levels, reinforcing a favorable view of the company’s valuation and outlook. Benzinga analyst update
• Positive Sentiment: Gilead outperformed the broader stock market in the latest session. The reports did not identify a new company-specific catalyst, suggesting the move may reflect market positioning and investor interest in the large-cap biopharmaceutical sector rather than a major fundamental announcement. Gilead Sciences Laps the Stock Market
• Neutral Sentiment: Gilead’s upcoming results remain a key focus. Recent coverage highlights expectations for an earnings decline and suggests the company lacks the historical estimate-revision and earnings-surprise trends that typically support a strong beat. Investors may therefore look closely at product sales, guidance, and pipeline progress in the next report. Analysts Estimate Gilead to Report a Decline in Earnings
• Negative Sentiment: Erste Group Bank lowered its FY2027 EPS forecast for Gilead to $9.59 from $9.65. Although the reduction is small, it indicates slightly softer expectations for longer-term earnings growth and may weigh on sentiment at a time when investors are assessing the sustainability of Gilead’s earnings outlook.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.